Effect of Vitamin C on Stress in Peritoneal Dialysis Patients

Effect of Vitamin C on Oxidative Stress in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016050227675N2

Enrollment

Registered

2017-01-20

Start date

2016-12-25

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal dialysis patients. End-stage renal disease

Interventions

Intervention 1: Group I (intervention group): Prescription 250 miligram of vitamin c and 250 miligram of vitamin B6 once in one day for 8 weeks. Intervention 2: Group II (control group): Prescription

Treatment - Drugs

Placebo

Group I (intervention group): Prescription 250 miligram of vitamin c and 250 miligram of vitamin B6 once in one day for 8 weeks

Group II (control group): Prescription 250 mg of placebo capsule, once in one day for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Patients treated with peritoneal dialysis for more than six months; Patients with ages: 18-65 years old; Having a regular program of CAPD, three to four times swap by two liters isotonic or hypertonic glucose solution or icodextrin solution for at least 3 months. Exclusion Criteria: The patients With peritonitis or any other infection at least four weeks before sampling; The incidence of any chronic inflammatory disease; using non-steroidal and allopurinol and antioxidant drugs; Inadequate control of diabetes or HbA1c more than 7.5 %.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Peritoneum and serum total antioxidants capacity (TAC). Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous and peritoneal sampling and sent to the laboratory.;Malonyl dialdehyde (MDA). Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous and peritoneal sampling and sent to the laboratory.	—

Measure

Time frame

Peritoneum and serum total antioxidants capacity (TAC). Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous and peritoneal sampling and sent to the laboratory.;Malonyl dialdehyde (MDA). Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous and peritoneal sampling and sent to the laboratory.

—

Secondary

Measure	Time frame
Uric acid. Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;Albumin. Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;C-reactive protein (CRP). Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;Hemoglobin A1c (HbA1c). Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;Low density lipoprotein (LDL) and high density lipoprotein (HDL). Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;Fasting blood sugar. Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;Serum triglyceride. Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.	—

Measure

Time frame

Uric acid. Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;Albumin. Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;C-reactive protein (CRP). Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;Hemoglobin A1c (HbA1c). Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;Low density lipoprotein (LDL) and high density lipoprotein (HDL). Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;Fasting blood sugar. Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;Serum triglyceride. Timepoint: Before intervention and after completion of intervention in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarshid Padyab

Ahvaz Jundishapur University of Medical Sciences

s.nz1990@yahoo.com+98 61 3222 2922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026